Buprenorphine And Naloxone Film
NDC Package 47781-357-03
Package Information
Buprenorphine And Naloxone films is buprenorphine and naloxone sublingual film is indicated for treatment of opioid dependence. This formulation utilizes a film delivery system. Marketed by Alvogen Inc., this product is identified by NDC 47781-357 and is authorized under FDA application ANDA205954.
Identification & Billing
- RxCUI: 1010600 - buprenorphine HCl 2 MG / naloxone HCl 0.5 MG Sublingual Film
- RxCUI: 1010600 - buprenorphine 2 MG / naloxone 0.5 MG Sublingual Film
- RxCUI: 1010600 - buprenorphine 2 MG / naloxone 0.5 MG Buccal Film
- RxCUI: 1010604 - buprenorphine HCl 8 MG / naloxone HCl 2 MG Sublingual Film
- RxCUI: 1010604 - buprenorphine 8 MG / naloxone 2 MG Sublingual Film
Clinical Specifications
- Buccal - Administration directed toward the cheek, generally from within the mouth.
- Sublingual - Administration beneath the tongue.
Regulatory & Marketing
Hierarchy Structure
- 47781 - Alvogen Inc.
- 47781-357 - Buprenorphine And Naloxone
- 47781-357-03 - 30 POUCH in 1 CARTON / 1 FILM in 1 POUCH (47781-357-11)
- 47781-357 - Buprenorphine And Naloxone
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 47781-357-03 identifies a specific commercial package of 30 pouch in 1 carton / 1 film in 1 pouch (47781-357-11) of Buprenorphine And Naloxone Sublingual Film, a human prescription drug labeled by Alvogen Inc.. This film is formulated for buccal; sublingual use and contains buprenorphine hydrochloride; naloxone hydrochloride dihydrate as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Alvogen Inc. on February 11, 2019. The current certification is valid through December 31, 2027.
How is this Alvogen Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 47781035703. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 30 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.